Piramal Pharma Share Price Target 2024, 2025 to 2030

Piramal Pharma Limited (PPL) stands as a prominent player in the pharmaceutical industry, offering a wide array of products and services globally. With 17 advanced development and manufacturing facilities and a robust distribution network spanning over 100 countries, PPL is committed to delivering innovative solutions. Its divisions include Piramal Pharma Solutions (PPS), catering as an integrated Contract Development and Manufacturing Organization, Piramal Critical Care (PCC) specializing in Complex Hospital Generics, and the India Consumer Healthcare segment offering over-the-counter products. Additionally, PPL boasts strategic partnerships, including AbbVie Therapeutics India Private Limited, a joint venture with AbbVie Inc., excelling in ophthalmology therapy. The company’s progressive journey includes a 20% strategic growth investment from the Carlyle Group in October 2020, further solidifying its position as a leader in the global pharmaceutical landscape. As part of the esteemed Piramal Group, PPL contributes to the conglomerate’s diverse interests across various sectors, including pharma, financial services, and real estate, leveraging its global presence and a diverse workforce of over 10,000 professionals from 21 different nationalities spread across more than 30 countries.

Latest News on Piramal Pharma

Piramal Pharma Ltd continues to strengthen its global presence and expand its offerings in the pharmaceutical space. The company operates through three major business divisions: Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and India Consumer Healthcare. Piramal Pharma Solutions (PPS) provides integrated development and manufacturing services to both innovators and generic companies worldwide, operating across North America, Europe, and Asia. The company’s PCC division focuses on complex hospital generics, including inhalation anesthetics and injectable therapies, with a strong presence in the global hospital sector.

Piramal Pharma’s India Consumer Healthcare division addresses the growing demand for over-the-counter healthcare products, enhancing its footprint within the Indian market. The company boasts a global network, operating through 17 development and manufacturing facilities with a distribution reach in over 100 countries. Their commitment to innovation, healthcare solutions, and maintaining a strong international presence highlights their mission to positively impact the healthcare industry.

Shareholdings Patterns of Piramal Pharma

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters +	34.78%	35.02%	35.02%	35.02%	34.94%
FIIs +	35.01%	32.37%	32.51%	30.58%	31.41%
DIIs +	5.48%	8.01%	9.68%	12.12%	12.95%
Public +	24.32%	24.21%	22.41%	21.89%	20.20%
Others +	0.39%	0.38%	0.38%	0.37%	0.47%
No. of Shareholders	2,77,270	3,00,606	2,92,312	2,97,996	3,06,398

The shareholding patterns of Piramal Pharma Limited reflect a dynamic structure over recent quarters. As of June 2023, promoters held 34.78% of the company’s shares, with a slight increase to 35.02% by September and a gradual decline to 34.94% by June 2024. Foreign Institutional Investors (FIIs) exhibited a decreasing trend, dropping from 35.01% in June 2023 to 31.41% by June 2024. Conversely, Domestic Institutional Investors (DIIs) showed a significant upward trajectory, increasing their stake from 5.48% in June 2023 to 12.95% in June 2024, indicating growing institutional confidence in Piramal Pharma. The public shareholding also saw a decline from 24.32% to 20.20% during the same period, while the “Others” category slightly increased. The total number of shareholders rose from 277,270 in June 2023 to 306,398 in June 2024, reflecting increased retail participation. This shift in shareholding patterns illustrates a nuanced investor sentiment towards Piramal Pharma, with rising DII involvement potentially stabilizing the company’s ownership structure.

How to Purchase Piramal Pharma Shares in India?

Below are the trading platforms that you can use to purchase Piramal Pharma shares:

➤ Zerodha

➤ Upstox

➤ Groww

➤ AngelOne

➤ ICICIDirect

Piramal Pharma Share Price Target 2024, 2025 to 2030

Piramal Pharma Share Price Target 2024

When	Maximum Price	Minimum Price
October 2024	238.85	207.70
November 2024	248.41	216.01
December 2024	250.89	218.17

In October 2024, the maximum price is projected to reach ₹238.85, while the minimum could dip to ₹207.70. As we approach November 2024, the maximum price may rise slightly to ₹248.41, with the minimum at ₹216.01. By December 2024, the price is anticipated to stabilize, with the maximum at ₹250.89 and the minimum at ₹218.17.

Piramal Pharma Share Price Prediction 2025

When	Maximum Price	Minimum Price
January 2025	253.40	194.92
February 2025	255.96	196.89
March 2025	261.34	201.03
April 2025	258.75	199.04
May 2025	251.21	193.24
June 2025	262.52	201.94
July 2025	257.37	197.98
August 2025	265.33	204.10
September 2025	268.51	206.55
October 2025	275.49	211.92
November 2025	282.38	217.22
December 2025	295.09	226.99

Piramal Pharma Share Price Target 2026

When	Maximum Price	Minimum Price
January 2026	303.94	233.80
February 2026	296.34	227.96
March 2026	302.27	232.52
April 2026	308.44	237.26
May 2026	305.38	234.91
June 2026	313.02	240.78
July 2026	306.88	236.06
August 2026	316.37	243.36
September 2026	322.70	248.23
October 2026	331.09	254.69
November 2026	339.37	261.05
December 2026	347.85	267.58

Piramal Pharma Share Price Target 2027

When	Maximum Price	Minimum Price
January 2027	351.33	270.25
February 2027	360.34	277.18
March 2027	374.39	287.99
April 2027	367.05	282.35
May 2027	356.36	274.12
June 2027	372.40	286.46
July 2027	365.09	280.84
August 2027	376.39	289.53
September 2027	389.56	299.66
October 2027	399.69	307.45
November 2027	409.68	315.14
December 2027	419.92	323.02

Piramal Pharma Share Price Prediction 2028

When	Maximum Price	Minimum Price
January 2028	428.32	329.48
February 2028	439.30	337.93
March 2028	456.44	351.11
April 2028	447.49	344.22
May 2028	434.45	334.19
June 2028	454.00	349.23
July 2028	445.10	342.39
August 2028	458.87	352.98
September 2028	474.93	365.33
October 2028	487.28	374.83
November 2028	499.46	384.20
December 2028	511.94	393.80

Piramal Pharma Share Price Target 2029

When	Maximum Price	Minimum Price
January 2029	522.18	401.68
February 2029	535.57	411.98
March 2029	556.46	428.05
April 2029	545.55	419.65
May 2029	529.66	407.43
June 2029	553.49	425.76
July 2029	542.64	417.42
August 2029	559.42	430.33
September 2029	579.00	445.39
October 2029	594.06	456.97
November 2029	608.91	468.39
December 2029	624.13	480.10

Piramal Pharma Share Price Prediction 2030

When	Maximum Price	Minimum Price
January 2030	636.61	489.70
February 2030	652.94	502.26
March 2030	678.40	521.85
April 2030	665.10	511.62
May 2030	645.73	496.71
June 2030	674.79	519.07
July 2030	661.56	508.89
August 2030	682.02	524.63
September 2030	705.89	542.99
October 2030	724.24	557.11
November 2030	742.35	571.04
December 2030	760.90	585.31

In January 2030, the expected maximum price is projected to reach ₹636.61, with a minimum of ₹489.70. By February, the price is anticipated to increase slightly, with a projected maximum of ₹652.94 and a minimum of ₹502.26. As the months progress, the price is expected to rise steadily, reaching a maximum of ₹705.89 and a minimum of ₹542.99 by September. By December 2030, Piramal Pharma is projected to reach its annual peak with a maximum price of ₹760.90 and a minimum of ₹585.31, highlighting a strong upward trend for the company as the year closes.

Financial Condition of Piramal Pharma

	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales +	6,315	6,559	7,082	8,171	8,373
Expenses +	4,887	5,609	6,453	6,974	7,105
Operating Profit	1,428	950	629	1,197	1,268
OPM %	23%	14%	9%	15%	15%
Other Income +	230	319	272	172	161
Interest	163	198	344	448	437
Depreciation	545	586	677	741	752
Profit before tax	949	485	-120	179	241
Tax %	12%	22%	55%	90%
Net Profit +	835	376	-186	18	28
EPS in Rs			-1.41	0.13	0.22
Dividend Payout %	0%	18%	0%	82%

Piramal Pharma Ltd’s financial performance over the last few years reflects both challenges and resilience. From March 2021 to March 2024, the company’s sales grew steadily from ₹6,315 crore in 2021 to ₹8,373 crore in the TTM (Trailing Twelve Months). However, operating profit showed a fluctuating trend, starting at ₹1,428 crore in 2021, declining to ₹629 crore in 2023, and rebounding to ₹1,268 crore in 2024. This resulted in an improvement in the operating profit margin (OPM), which rose from 9% in March 2023 to 15% in the TTM.

Piramal Pharma Ltd faced higher expenses, increasing from ₹4,887 crore in 2021 to ₹7,105 crore in the TTM, which weighed on profitability. Additionally, interest costs rose sharply, peaking at ₹448 crore in 2023 before slightly decreasing to ₹437 crore in the TTM, reflecting the company’s debt management challenges.

The net profit trend is particularly notable, with a sharp decline from ₹835 crore in 2021 to a loss of ₹186 crore in 2023, but recovering to a marginal profit of ₹28 crore in the TTM. EPS (Earnings Per Share) showed improvement from a loss of ₹1.41 in March 2023 to a slight gain of ₹0.22 in the TTM.

Overall, while Piramal Pharma Ltd has seen growing sales and a return to profitability, the volatility in profit margins and high-interest costs highlight the need for continued financial discipline and strategic focus.

FAQS